Phaseline

Companies › Actinium Pharmaceuticals

Actinium Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Iomab-B
Anti-CD117 monoclonal antibody conjugated to iodine-131
CD117Phase 3Acute Myeloid Leukemia; Non Hodgkin LymphomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02665065Iomab-BPhase 3Acute Myeloid LeukemiaOncologyDec 2026
NCT06768905Iomab-BPhase 1Non Hodgkin LymphomaOncologyMay 2029

From the company's SEC filings

Cash of $36m on 2026-06-30; operating cash outflow about $22m a year; runway about 20 months at that burn, to Feb 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

CD117 (1)

Companies with the same targets

–

Companies built like this

Immutep S.A.S. Genelux Imunon ADC Therapeutics Candel Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.